CFTR Modulator Therapy For N1303K Mutations

被引：0
|
作者：
Barletta, P. [1 ]
Ortiz, M. G. Tupayachi [1 ]
Baumlin, N. [2 ]
Salathe, M. A. [2 ]
机构：
[1] Univ Miami Hosp, Pulm & Crit Care, Miami, FL USA
[2] Univ Kansas, Med Ctr, Internal Med, Kansas City, KS 66103 USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2023年 / 207卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A4321
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Rescue of NBD2 Mutants N1303K and S1235R of CFTR by Small-Molecule Correctors and Transcomplementation
    Rapino, Daniele
    Sabirzhanova, Inna
    Lopes-Pacheco, Miqueias
    Grover, Rahul
    Guggino, William B.
    Cebotaru, Liudmila
    PLOS ONE, 2015, 10 (03):
  • [22] Elexacaftor/Tezacaftor/Ivacaftor Effectiveness in N1303K Variant in Adult People With Cystic Fibrosis
    Canan, Mariane Goncalves alves Martynychen
    Sokoloski, Caroline Souza
    Severo, Carolina Rossetti
    Rached, Samia Zahi
    Athanazio, Rodrigo Abensur
    ARCHIVOS DE BRONCONEUMOLOGIA, 2024, 60 (08): : 526 - 528
  • [23] Pseudo-Bartter's syndrome in an Egyptian infant with cystic fibrosis mutation N1303K
    Wahab, AA
    Janahi, IA
    Marafia, MM
    JOURNAL OF TROPICAL PEDIATRICS, 2004, 50 (04) : 242 - 244
  • [24] Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rare CFTR variants: a viewpoint
    Burgel, Pierre-Regis
    Sermet-Gaudelus, Isabelle
    Girodon, Emmanuelle
    Kanaan, Reem
    Le Bihan, Jean
    Remus, Natascha
    Ravoninjatovo, Bruno
    Grenet, Dominique
    Porzio, Michele
    Houdouin, Veronique
    Le Clainche-Viala, Laurence
    Durieu, Isabelle
    Nove-Josserand, Raphaele
    Languepin, Jeanne
    Coltey, Berangere
    Guillaumot, Anne
    Audousset, Camille
    Chiron, Raphael
    Weiss, Laurence
    Fajac, Isabelle
    Da Silva, Jennifer
    Martin, Clemence
    EUROPEAN RESPIRATORY JOURNAL, 2024, 63 (01)
  • [25] Response to Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis with the N1303K mutation: Case report and review of the literature
    Ortiz, Maria G. Tupayachi
    Baumlin, Nathalie
    Yoshida, Makoto
    Salathe, Matthias
    HELIYON, 2024, 10 (05)
  • [26] Evaluation of elexacaftor-tezacaftor-ivacaftor treatment in individuals with cystic fibrosis and CFTR N1303K in the USA: a prospective, multicentre, open-label, single-arm trial
    Solomon, George M.
    Linnemann, Rachel W.
    Rich, Rachel
    Streby, Ashleigh
    Buehler, Brian
    Hunter, Eric
    Vijaykumar, Kadambari
    Hunt, William R.
    Brewington, John J.
    Rab, Andras
    Bai, Shasha P.
    Westbrook, Adrianna L.
    McNicholas-Bevensee, Carmel
    Hong, Jong
    Manfredi, Candela
    Barilla, Cristina
    Suzuki, Shingo
    Davis, Brian R.
    Sorscher, Eric J.
    LANCET RESPIRATORY MEDICINE, 2024, 12 (12): : 947 - 957
  • [27] N1303K and IVS8-5T, clinical presentation within a family with atypical cystic fibrosis
    Van Hoorenbeeck, Kim
    Storm, Katrien
    van den Ende, Jenneke
    Biervliet, Martine
    Desager, Kristine N.
    JOURNAL OF CYSTIC FIBROSIS, 2007, 6 (03) : 220 - 222
  • [28] Preferred half-conductance state of a CFTR processing mutant - N1303K.
    Zerhusen, B
    Xie, JX
    Zhao, JY
    Drumm, ML
    Davis, PB
    Ma, JJ
    BIOPHYSICAL JOURNAL, 2004, 86 (01) : 286A - 286A
  • [29] COMBINATION POTENTIATOR THERAPY FOR CYSTIC FIBROSIS CAUSED BY MUTANT CFTRS, INCLUDING N1303K AND W1282X, THAT ARE POORLY RESPONSIVE TO SINGLE POTENTIATORS
    Haggie, Peter M.
    PEDIATRIC PULMONOLOGY, 2018, 53 : 111 - 111
  • [30] RESCUE OF N1303K AND S1235R MUTATIONS BY TRANSCOMPLEMENTATION AND SMALL MOLECULE CORRECTORS, C3, C4 AND C18
    Rapino, D.
    Cebotaru, L.
    Guggino, W. B.
    PEDIATRIC PULMONOLOGY, 2013, 48 : 214 - 214
12345